Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Zimmer Biomet Holdings, Inc. (ZBH) — XLV Health Care · S&P 500 Profile |捷邁邦美公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Zimmer Biomet Holdings, Inc. (ZBH) — Business, History & S&P 500 Profile | 捷邁邦美公司介紹

Zimmer Biomet Holdings, Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #416 · 捷邁邦美公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 4, 2026
Financials: FY2025
MARKET CAP
$18.51B
Nov 4, 2026
S&P 500 WEIGHT
0.03%
Rank #416 · Nov 4, 2026
SECTOR RANK
#49
Health Care · Nov 4, 2026
S&P 500 RANK
#416
0.03% · Nov 4, 2026

SNAPSHOT

TickerZBH
CompanyZimmer Biomet Holdings, Inc.
GICS sector / industryHealth Care (XLV) / Health Care Equipment
S&P 500 rank (by weight)#416 · 0.03% (Nov 4, 2026)
Sector rank#49 of 60 in Health Care (Nov 4, 2026)
HeadquartersWarsaw, Indiana
Founded1927
CEOIvan Tornos (Chairman, President and CEO)
Employees~17,000 (as of December 31, 2025)
Market cap$18.51B (Nov 4, 2026)
SEC filingsEDGAR — CIK 0001136869

WHAT IT DOES

Zimmer Biomet Holdings, Inc. is a global medical technology company designing, manufacturing and marketing orthopaedic reconstructive products, sports medicine, extremities, trauma and surgical products, headquartered in Warsaw, Indiana. Its implants and instruments help surgeons replace damaged knees, hips, shoulders and other joints.

Its one-line model: sell high-value implants and the instruments and technology that go with them into hospital procedures, and grow with ageing populations and rising procedure volumes. Fiscal 2025 net sales were $8.23B, with operating profit of $1.10B and net earnings attributable to Zimmer Biomet of $705.1M.

The moat is surgeon adoption and installed technology: surgeons train on specific systems, hospitals standardise around them, and robotics and data tools deepen the relationship. Growth comes from robotics, the Paragon 28 foot-and-ankle franchise, and international markets.

BUSINESS SEGMENTS

AmericasThe largest geographic market, covering the United States and Latin America orthopaedic sales.
Europe, Middle East and Africa (EMEA)Europe, the Middle East and Africa orthopaedic sales.
Asia PacificAsia Pacific orthopaedic sales.
Reportable operating segments per the 10-K are geographic, based on senior management structure. Sales by product category (not reportable segments): Knees $3,322M; Hips $2,094M; S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) $2,150M; Technology & Data, Bone Cement and Surgical $665.5M (last figure derived as the remainder of $8,231.5M).

HISTORY

YearMilestone
1927Justin O. Zimmer founds Zimmer Manufacturing Company in Warsaw, Indiana, initially making aluminium splints.
2001Zimmer is spun off from Bristol-Myers Squibb (August 6, 2001) and begins NYSE trading as ZMH.
2015Acquisition of Biomet Inc. completes (June 24, 2015), forming Zimmer Biomet Holdings; ticker changes to ZBH.
2025Acquires Paragon 28, Inc. (foot and ankle), completed April 21, 2025, for approximately $1.1B.
2025Agrees to acquire Monogram Technologies (AI-driven orthopaedic robotics, ~$177M); completed October 7, 2025.

COMPETITIVE POSITION

  • Scale in orthopaedics: one of the largest global makers of knee and hip implants, with a broad surgeon network and hospital relationships.
  • Robotics and data: the Monogram acquisition and technology portfolio push surgery toward robotic assistance and data-guided planning.
  • Breadth across the joint: knees, hips, sports medicine, extremities and trauma cover most reconstructive procedures in one supplier.
  • Competition set: Johnson & Johnson MedTech, Stryker and Smith+Nephew (named in the 2025 10-K summary).

FINANCIAL SNAPSHOT

Total revenue$8.23B (FY2025 revenue)
Operating income$1.10B (FY2025 operating income)
Net income$705.1M (FY2025 net income)
Diluted EPS$3.55 (FY2025 diluted EPS)
Source: Zimmer Biomet Holdings fiscal 2025 Form 10-K (year ended December 31, 2025; filed February 20, 2026) and Q4 2025 earnings release. Exact figures: net sales $8,231.5M; operating profit $1,098.1M; net earnings attributable to Zimmer Biomet Holdings, Inc. $705.1M (total net earnings $705.2M, the $0.1M difference being noncontrolling interest); diluted EPS $3.55. Adjusted diluted EPS $8.20 is non-GAAP and is not the headline figure.

KEY RISKS

  • Pricing and reimbursement pressure: hospitals and payers push implant prices down, and procedure volumes follow demographics and elective-surgery cycles.
  • Product and recall risk: implant quality issues or recalls carry liability, cost and surgeon-trust consequences.
  • Integration execution: recent acquisitions (Paragon 28, Monogram) must be integrated without disrupting sales or margins.
  • Currency exposure: a large non-US business makes reported results sensitive to foreign-exchange moves.

WHY IT MATTERS FOR THE S&P 500

Zimmer Biomet is a small-weight health care constituent: rank #416 by weight at 0.03% as of Nov 4, 2026, and #49 in Health Care. As one of the largest orthopaedic implant makers, it is a direct read on elective procedure volumes and the ageing-driven demand for joint replacement.

SOURCES & METHODOLOGY

Financials, segments, headquartersZimmer Biomet Holdings fiscal 2025 Form 10-K via SEC EDGAR and Q4 2025 earnings release (see Financial Snapshot note); headquarters, CEO and history via the Form 10-K and Wikipedia company profile
Index weight & ranksSlickcharts S&P 500 weights, fetched Nov 4, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS)
Market cap$18.51B (Slickcharts, Nov 4, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

ZBH

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號ZBH
公司Zimmer Biomet Holdings, Inc.(捷邁邦美)
GICS 板塊/行業健康護理(XLV)/醫療設備
標普500排名(按權重)#416 · 0.03%(Nov 4, 2026)
板塊內排名健康護理板塊 #49(共 60 家)(Nov 4, 2026)
總部美國印第安納州華沙
成立1927年
執行長Ivan Tornos(董事長、總裁兼執行長)
員工約17,000人(截至2025年12月31日)
市值$18.51B(Nov 4, 2026)
SEC 申報EDGAR — CIK 0001136869

業務概覽

Zimmer Biomet Holdings, Inc. 是全球醫療科技公司,設計、製造與銷售骨科重建產品、運動醫學、四肢、創傷及外科產品,總部位於印第安納州華沙。植入物與器械協助外科醫生置換受損的膝、髖、肩及其他關節。

其一句話商業模式是:向醫院手術銷售高價值植入物及配套器械與技術,並隨人口老化與手術量上升而增長。2025 財年淨銷售 82.32 億美元,營業利潤 10.98 億美元,歸屬 Zimmer Biomet 淨利潤 7.05 億美元。

護城河是外科醫生採用與已安裝技術:外科醫生接受特定系統培訓,醫院圍繞系統標準化,機械人與數據工具加深關係。增長來自機械人、Paragon 28 足踝業務與國際市場。

業務板塊

美洲最大的地區市場,涵蓋美國與拉丁美洲骨科銷售。
歐洲、中東及非洲歐洲、中東與非洲骨科銷售。
亞太亞太地區骨科銷售。
按 10-K,可報告經營板塊按地區劃分,依據高級管理層結構。按產品類別銷售(並非可報告板塊):膝關節 33.22 億美元;髖關節 20.94 億美元;S.E.T.(運動醫學、四肢、創傷、顱頜面及胸腔)21.50 億美元;技術與數據、骨水泥及外科 6.655 億美元(最後數字為 82.315 億美元的餘額推算)。

歷史

年份里程碑
1927Justin O. Zimmer 在印第安納州華沙創立 Zimmer Manufacturing Company,初期生產鋁製夾板。
2001Zimmer 自 Bristol-Myers Squibb 分拆(2001 年 8 月 6 日),以 ZMH 在紐約證券交易所開始交易。
2015收購 Biomet Inc. 完成(2015 年 6 月 24 日),組成 Zimmer Biomet Holdings;股票代號改為 ZBH。
2025收購 Paragon 28, Inc.(足踝業務),2025 年 4 月 21 日完成,約 11 億美元。
2025同意收購 Monogram Technologies(人工智能驅動骨科機械人,約 1.77 億美元);2025 年 10 月 7 日完成。

競爭地位

  • 骨科規模:全球最大的膝關節與髖關節植入物製造商之一,擁有廣泛的外科醫生網絡與醫院關係。
  • 機械人與數據:Monogram 收購與技術組合推動手術走向機械人輔助與數據引導規劃。
  • 關節全覆蓋:膝、髖、運動醫學、四肢與創傷產品涵蓋大多數重建手術,可由單一供應商提供。
  • 競爭對手:Johnson & Johnson MedTech、Stryker 與 Smith+Nephew(2025 年 10-K 摘要所列)。

財務快照

總收入82.32 億美元(2025 財年收入)
營業利潤10.98 億美元(2025 財年營業利潤)
淨利潤7.05 億美元(2025 財年淨利潤)
稀釋 EPS3.55 美元(2025 財年稀釋 EPS)
來源:Zimmer Biomet Holdings 2025 財年 Form 10-K(截至 2025 年 12 月 31 日;2026 年 2 月 20 日申報)及 2025 年第四季業績公佈。精確數字:淨銷售 82.315 億美元;營業利潤 10.981 億美元;歸屬 Zimmer Biomet Holdings, Inc. 淨利潤 7.051 億美元(淨利潤合計 7.052 億美元,0.001 億美元差額為非控股權益);稀釋 EPS 3.55 美元。經調整稀釋 EPS 8.20 美元為非 GAAP 數字,並非 headline 數字。

主要風險

  • 定價與報銷壓力:醫院與付款方壓低植入物價格,手術量跟隨人口結構與擇期手術週期。
  • 產品與召回風險:植入物質量問題或召回帶來責任、成本與外科醫生信任後果。
  • 整合執行:近期收購(Paragon 28、Monogram)須在不擾亂銷售或利潤率下整合。
  • 貨幣風險:龐大的非美國業務令申報業績受外匯波動影響。

對標普500的重要性

Zimmer Biomet 是權重較小的健康護理成分股:按權重排名 #416,權重 0.03%(以 2026 年 11 月 4 日為準),健康護理板塊內排名 #49。作為最大的骨科植入物製造商之一,它是擇期手術量與老化驅動的關節置換需求的直接指標。

來源與方法

財務、板塊、總部Zimmer Biomet Holdings 2025 財年 Form 10-K 數據,經 SEC EDGAR 及 2025 年第四季業績公佈(見財務快照附註);總部、執行長與歷史經 Form 10-K 及維基百科公司資料
指數權重與排名Slickcharts 標普 500 權重,Nov 4, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS)
市值$18.51B(Slickcharts,Nov 4, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

ZBH

來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · ZBH
Data as of Nov 4, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · Nordson Corporation (NDSN) — XLI Industrials · S&P 500 Profile |Nordson公司介紹Next · Reddit, Inc. (RDDT) — XLC Communication Services · S&P 500 Profile |Reddit公司介紹

Entered 2026-11-04 02:18 · updated 2026-11-15 00:19 · rev 6